AroCell expands the indication of use for AroCell TK 210 ELISA in Europe

AroCell announces today the expansion of the indication for use for the CE marked AroCell TK 210 ELISA with clinical use in prostate cancer treatment.

The AroCell TK 210 ELISA kit can now be used for measuring TK1 as a prognostic/predictive marker in prostate cancer in clinical and hospital laboratories to aid oncologists when stratifying patients for treatment.

The CE-mark is a certification mark that indicates conformity to the directive for a product in Europe’s internal market (EU/EES). This is a major step in increasing the future market potential and sales of the AroCell TK 210 ELISA kit for clinical use in Europe.

“We are happy to be able to make this extension of the indication for use for the CE marked AroCell TK 210 ELISA, which makes it possible to use AroCell TK 210 ELISA for prostate cancer. This is part of our regulatory strategy for Europe, to expand the intended use based on clinical data” says Anders Hultman, CEO of AroCell.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com